Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Enliven Therapeutics Inc shares valued at $1,351,762 were sold by Patel Anish on Jan 09 ’26. At $27.99 per share, Patel Anish sold 48,300 shares. The insider’s holdings dropped to 215,011 shares worth approximately $5.6 million following the completion of this transaction.
Also, Lyssikatos Joseph P sold 91,198 shares, netting a total of over 2,482,578 in proceeds. Following the sale of shares at $27.22 each, the insider now holds 765,188 shares.
Before that, Lyssikatos Joseph P had sold 41,302 shares from its account. In a trade valued at $993,436, the CHIEF SCIENTIFIC OFFICER traded Enliven Therapeutics Inc shares for $24.05 each. Upon closing the transaction, the insider’s holdings decreased to 41,302 shares, worth approximately $22.31 million.
As published in their initiating research note from Goldman on June 16, 2025, Enliven Therapeutics Inc [ELVN] has been a Buy and the price target has been revised to $37. Analysts at BTIG Research started covering the stock with ‘”a Buy”‘ outlook in a report released in mid December. As of September 09, 2024, H.C. Wainwright has initiated its “Buy” rating for ELVN. Earlier on June 11, 2024, Robert W. Baird initiated its rating. Their recommendation was “an Outperform” for ELVN stock.
Analyzing ELVN Stock Performance
On last trading session, Enliven Therapeutics Inc [NASDAQ: ELVN] rose 1.17% to $26.05. The stock’s lowest price that day was $24.89, but it reached a high of $27.395 in the same session. During the last five days, there has been a surge of approximately 68.39%. Over the course of the year, Enliven Therapeutics Inc shares have jumped approximately 18.03%.
Is Enliven Therapeutics Inc subject to short interest?
Stocks of Enliven Therapeutics Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.32 million shares to 8.31 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 8.0 million shares. A jump of 3.8% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.74 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.74.
Which companies own the most shares of Enliven Therapeutics Inc (ELVN)?
In terms of Enliven Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 39 in the next 12 months, up nearly 51.46% from the previous closing price of $25.75. Analysts anticipate Enliven Therapeutics Inc stock to reach 52 by 2026, with the lowest price target being 39. In spite of this, 0 analysts ranked Enliven Therapeutics Inc stock as nan at the end of 2026. On April 09, 2024, Mizuho assigned a price target of “a Buy” to the stock and initiated coverage with a $34.
